Traws Pharma, Inc. TRAW 深 沪
已收盘 07-02 16:00:00 美东时间
0.7677
-0.043
-5.34%
华盛通- 最 高0.85
- 今 开0.82
- 成交量 23.86万股
- 最 低 0.7571
- 昨 收 0.811
- 总市值 1163.12万
- 52周最高 3.265
- 市盈率 静 0.70
- 换手率 1.57%
- 52周最低 0.64
- 委 比 56.33%
- 总股本 1515.07万
- 历史最高 1751062.50
- 量 比 1.17
- 振 幅 11.45%
- 历史最低 0.64
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ladenburg Thalmann Downgrades Traws Pharma to Neutral
Ladenburg Thalmann analyst Kevin DeGeeter downgrades Traws Pharma (NASDAQ:TRAW) from Buy to Neutral.
06-16 00:11
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study
Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program. The decline follows a recent update indicating that the planned Phase 2a human influenza challenge study for its lead compound, tivoxavir marboxil,...
06-15 23:10
10 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Gelteq (NASDAQ:GELS) shares moved upwards by 50.5% to $1.49 during Monday's pre-market session. The company's market cap stands at $10.6 million. Quantum Cyber (NASDAQ:QUCY) shares moved upwards by 15.58% to $2.0. The market value of their outstanding shares is at $39.3 million. Cypherpunk T...
06-15 20:05
Why Tower Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of Tower Semiconductor Ltd (NASDAQ:TSEM) rose sharply in pre-market trading. IQE and Tower Semiconductor disclosed a multi-year Indium Phosphide (InP) epiwafer supply agreement for AI-driven data centre optical connectivity while resolving all prior IP disputes. Tower Semiconductor shares jum...
06-15 16:27
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
06-06 02:24
Traws Pharma Announces Advancement Of Its Novel Proprietary Broad-Spectrum Combination Anti-Viral Agent With Potential Utility Against Hantavirus, Ebola and Lassa
Traws Pharma, Inc. (NASDAQ:TRAW), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced the advancement of a novel proprietary broad-spectrum combination
05-27 20:48
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
HC Wainwright & Co. Reiterates Buy on Traws Pharma, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Buy and maintains $8 price target.
05-20 18:45
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
Traws Pharma Q1 EPS $(0.53) Beats $(0.56) Estimate
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 66.46 percent increase over losses of $(1.58) per share from the
05-15 19:09
